Archive · 27 Jul 2025
New Malaria Vaccine AdFalciVax Shows Promise
Scientists are working on a new malaria vaccine called AdFalciVax.
It uses parts of the malaria parasite to help your body fight it off.
The vaccine is designed to stop the disease from spreading and causing illness.
It has shown promising results in mice and India has made significant progress in decreasing malaria cases.
The vaccine is not yet for sale, and is going through further research before being released.
ICMR is seeking partners to launch and sell AdFalciVax, a new malaria vaccine.
AdFalciVax is a chimeric recombinant vaccine targeting Plasmodium falciparum.
The vaccine uses two proteins: CSP to prevent infection and Pro6C to prevent community spread.
AdFalciVax provided over 90% protection against infection in mice, but human trials are pending.
India has significantly reduced malaria cases and deaths, exiting the HBHI group.
- Who
- The Indian Council of Medical Research (ICMR).
- What
- Development of the AdFalciVax malaria vaccine.
- When
- The vaccine is currently in development.
- Where
- The vaccine was developed at ICMR's Regional Medical Research Centre in Bhubaneshwar.
- Why
- To combat malaria and reduce its impact in India and globally.
Issues
Viewpoints
Vaccine Effectiveness
Issues
AdFalciVax is ineffective against Plasmodium vivax, the cause of malaria in India.
Viewpoints
AdFalciVax targets Plasmodium falciparum, which is the most common cause of malaria.
- Vaccine Name
- AdFalciVax
- Target Pathogen
- Plasmodium falciparum
- Vaccine Type
- Chimeric recombinant
- ICMR's Goal
- Partner with a company for trials and production
- India's Progress
- Exited HBHI group
- 2023 malaria cases
- 2 million